Analogix develops prepacked columns and automated instrumentation for compound purification.

Varian acquired Analogix for approximately $11 million in cash. The transaction also includes future milestone fees over three years that could reach $4 million.

Varian says that it decided to buy Analogix to strengthen its product portfolio especially in the area of laboratory consumables. Analogix focuses on the development of prepacked columns and instrumentation for automated compound purification using flash chromatography.

“The acquisition of Analogix is strategic to the advancement of Varian’s goal to grow applications-based consumables products and to further broaden its product offering to the pharmaceutical industry,” comments Garry Rogerson, president and CEO, Varian. “Analogix has demonstrated an ability to successfully meet customer needs in the area of drug discovery and to grow its business rapidly in North America. Analogix products will now be distributed more effectively on a global basis via Varian’s worldwide distribution network.”

Previous articleEpix Achieves Milestone for Second Discovery Program in GSK Partnership
Next articleMerck & Co. Inks Deal to Advance GTx’ SARMs for $40M Upfront